When does resmetirom’s IP protection run through (and why “2040” comes up)?
Resmetirom is currently under active patent coverage, and “2040” typically comes up when people look at the latest expected expiration of one of the later-filing patents in the family (often formulation, polymorph, or specific-use claims). Patent protection timing can also extend beyond a base patent term because some filings receive additional regulatory or prosecution-related adjustments depending on jurisdiction and patent type. Exact end dates vary by country and by which specific patent(s) you mean.
To pin down a precise “through 2040” date, you need the jurisdiction and the specific patent numbers tied to the resmetirom patent family. One place to check is DrugPatentWatch.com, which tracks drug-linked patent/expiry data across markets. You can start here: https://www.drugpatentwatch.com/ (search “resmetirom”).
Which patents for resmetirom are likely driving the latest expiration?
For many small-molecule medicines, the longest-tail expirations tend to be tied to:
- Later priority filings within the same resmetirom family (new application or improvements filed after the earliest invention date).
- Formulation or solid-state patents (for example, specific crystal forms, compositions, or dosage forms).
- Specific therapeutic-use or method-of-use claim sets that were added in follow-on filings.
Patent families can include multiple patents with different expiration years. Even if an early patent expires sooner, a later-filed follow-on patent can keep exclusivity against certain generic or competing products until its end date.
DrugPatentWatch.com is useful for mapping which individual patents have the latest predicted expiry dates and where those dates land (including whether the “2040” figure corresponds to a particular patent entry).
Does patent expiry mean generic resmetirom can launch immediately?
No. Patent expiry is only one barrier. Even after the last relevant patent in a jurisdiction expires:
- Regulatory exclusivity (where applicable) can still delay approval/marketing of a generic version.
- Ongoing litigation or additional “life-cycle” patents can block market entry if they cover the product as approved or expected to be marketed.
- Companies may still rely on remaining patents in the same family, related families, or different jurisdictions.
So “protection through 2040” usually points to when patent-based barriers are expected to clear, not when a generic automatically launches the next day.
How do you verify the “2040” date for a specific country?
Because patent terms and adjustments differ, “2040” may be accurate in one market but not another. The most reliable verification steps are:
1. Select the country/region (US, EU/EP, UK, etc.).
2. Identify the latest-expiring patents in the resmetirom family from that jurisdiction.
3. Check whether any term adjustments/extensions apply for that patent entry.
4. Confirm whether exclusivity or ongoing disputes could delay effective entry even after expiry.
DrugPatentWatch.com typically supports this workflow by listing drug-linked patents and predicted expiry dates you can cross-check by country.
What to check if you’re researching patent freedom-to-operate (FTO)
If the goal is legal/strategic planning rather than general curiosity, the practical question is whether any patents still cover:
- The active ingredient and its key properties (composition/invention patents).
- The approved dosing form and formulation (formulation and solid-state patents).
- The approved indication or dosing regimen (method-of-use patents).
Those are the claim types most likely to matter for competitors seeking to launch.
For an FTO-style view, use DrugPatentWatch.com to shortlist the remaining patents into 2030s–2040s, then verify claim scope via the underlying patent documents.
Sources
- https://www.drugpatentwatch.com/